Leonid Heifets

7.8k citations

98 papers · 5.7k indexed · 1 hit paper · h-index 44

Co-authors: Pamela J. Lindholm-Levy Kevin O. Kisich Michael D. Iseman Svetlana Gelperina N Mor Michael H. Cynamon M D Iseman Max Salfinger
Topics: Tuberculosis Research and Epidemiology (73 papers)Mycobacterium research and diagnosis (71 papers)Quinazolinone synthesis and applications (13 papers)
Cited by: Infectious Diseases Molecular Medicine Epidemiology
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences American Journal of Respiratory and Critical Care Medicine
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Leonid Heifets

97 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

2005 543 citations Svetlana Gelperina, Kevin O. Kisich et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers

Countries citing papers authored by Leonid Heifets

Since Specialization

Citations

This map shows the geographic impact of Leonid Heifets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonid Heifets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonid Heifets more than expected).

Fields of papers citing papers by Leonid Heifets

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonid Heifets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonid Heifets. The network helps show where Leonid Heifets may publish in the future.

Co-authorship network of co-authors of Leonid Heifets

This figure shows the co-authorship network connecting the top 25 collaborators of Leonid Heifets. A scholar is included among the top collaborators of Leonid Heifets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonid Heifets. Leonid Heifets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment 2012 ·American Journal of Respiratory and Critical Care Medicine ·Jakko van Ingen,Eric F. Egelund,Adrah Levin,Sarah Elizabeth Totten,Martin J. Boeree,Johan W. Mouton,Rob E. Aarnoutse,Leonid Heifets,Charles A. Peloquin,Charles L. Daley	146
2	Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? 2011 ·Infection Genetics and Evolution ·Jakko van Ingen,Martin J. Boeree,Dick van Soolingen,Michael D. Iseman,Leonid Heifets,Charles L. Daley	26
3	Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs 2008 ·Tuberculosis ·Woo Jin Chung,Andrei Kornilov,Benjamin H. Brodsky,Michael Higgins,(unknown),Leonid Heifets,Michael H. Cynamon,John T. Welch	14
4	Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis 2007 ·International Journal of Pharmaceutics ·Kevin O. Kisich,Svetlana Gelperina,Michael Higgins,Steven Ray Wilson,Е. В. Шипуло,(unknown),Leonid Heifets	101
5	Ancestral antibiotic resistance in Mycobacterium tuberculosis 2005 ·Proceedings of the National Academy of Sciences ·Rowan P. Morris,Liem Nguyen,John Gatfield,Kevin Visconti,Kien T. Nguyen,Dirk Schnappinger,Sabine Ehrt,Yang Liu,Leonid Heifets,Jean Pieters,Gary K. Schoolnik,Charles J. Thompson	248
6	The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosisbreakdown → 2005 ·American Journal of Respiratory and Critical Care Medicine ·Svetlana Gelperina,Kevin O. Kisich,Michael D. Iseman,Leonid Heifets	543
7	Cough-generated Aerosols of Mycobacterium tuberculosis 2003 ·American Journal of Respiratory and Critical Care Medicine ·Kevin P. Fennelly,John W. Martyny,(unknown),Ian M. Orme,(unknown),Leonid Heifets	245
8	Mycobacterium terrae: Case Reports, Literature Review, and In Vitro Antibiotic Susceptibility Testing 2000 ·Clinical Infectious Diseases ·Debra S. Smith,Pamela J. Lindholm-Levy,Gwen A. Huitt,Leonid Heifets,James L. Cook	58
9	Clarithromycin or Rifabutin Alone or in Combination for Primary Prophylaxis ofMycobacterium aviumComplex Disease in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Trial 2000 ·The Journal of Infectious Diseases ·Constance A. Benson,Paige L. Williams,David L. Cohn,Simone Becker,(unknown),Thomas Nevin,Joyce A. Korvick,Leonid Heifets,Carroll Child,Michael M. Lederman,Richard C. Reichman,William G. Powderly,Gerard Notario,(unknown),Richard Hafner	62
10	A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients 1999 ·David L. Cohn,Evelyn J. Fisher,(unknown),James S. Hodges,(unknown),Carroll Child,(unknown),Cynthia L. Gibert,Wafaa El‐Sadr,Richard Hafner,Joyce A. Korvick,Mary E. Ropka,Leonid Heifets,(unknown),Donna J. Munroe,C. Robert Horsburgh	1
11	A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin 1999 ·David L. Cohn,Evelyn J. Fisher,(unknown),James S. Hodges,(unknown),Carroll Child,(unknown),Cynthia L. Gibert,Wafaa El‐Sadr,Richard Hafner,Joyce A. Korvick,Mary E. Ropka,Leonid Heifets,(unknown),Donna J. Munroe,C. Robert Horsburgh	1
12	Prospective Randomized Trial of Four Three‐Drug Regimens in the Treatment of DisseminatedMycobacterium aviumComplex Disease in AIDS Patients: Excess Mortality Associated with High‐Dose Clarithromycin 1999 ·Clinical Infectious Diseases ·David L. Cohn,Evelyn J. Fisher,Grace Peng,James S. Hodges,(unknown),Carroll Child,(unknown),Cynthia L. Gibert,Wafaa El‐Sadr,Richard Hafner,Joyce A. Korvick,Mary E. Ropka,Leonid Heifets,(unknown),(unknown),C. Robert Horsburgh	43
13	Once Weekly Azithromycin Therapy for Prevention ofMycobacterium aviumComplex Infection in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial 1998 ·Clinical Infectious Diseases ·Edward C. Oldfield,W. Jeffrey Fessel,Michael W. Dunne,G. Dickinson,Mark R. Wallace,W. Russell Byrne,Raymond T. Chung,Kenneth F. Wagner,Scott F. Paparello,(unknown),G. P. Melcher,(unknown),(unknown),(unknown),Leonid Heifets,Jonathan D. Berman	59
14	Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis 1997 ·American Journal of Respiratory and Critical Care Medicine ·Richard Hafner,(unknown),David J. Wright,Nancy E. Dunlap,Merrill J. Egorin,Mary E. Enama,K Muth,Charles A. Peloquin,(unknown),Leonid Heifets	34
15	Quantitation of mycobacteria in blood specimens from patients with AIDS 1994 ·Tubercle and Lung Disease ·(unknown),(unknown),(unknown),Leonid Heifets	11
16	Low Serum Levels of Oral Antimycobacterial Agents in Patients with Disseminated Mycobacterium avium Complex Disease 1993 ·The Journal of Infectious Diseases ·Steven Gordon,C. Robert Horsburgh,Charles A. Peloquin,J. A. Havlik,Beverly Metchock,Leonid Heifets,J. E. McGowan,Suzanne Thompson	54
17	Minimal Inhibitory Concentrations of Rifabutin, Ciprofloxacin, and Ofloxacin against Mycobacterium tuberculosis Isolated before Treatment of Patients in Taiwan 1989 ·American Review of Respiratory Disease ·(unknown),Jen-Fu Shih,Pamela J. Lindholm-Levy,Leonid Heifets	25
18	Clofazimine and other rimino-compounds: Minimal inhibitory and minimal bactericidal concentrations at different pHs for mycobacterium avium complex 1988 ·Tubercle ·Pamela J. Lindholm-Levy,Leonid Heifets	30
19	Minimal Inhibitory Concentrations of Isoniazid, Rifampin, Ethambutol, and Streptomycin against Mycobacterium tuberculosis Strains Isolated before Treatment of Patients in Taiwan 1988 ·American Review of Respiratory Disease ·(unknown),(unknown),Tao Lin,Leonid Heifets	23
20	Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against mycobacterium tuberculosis and mycobacterium avium complex 1987 ·Tubercle ·Leonid Heifets,Pamela J. Lindholm-Levy	69

About Leonid Heifets

Leonid Heifets is a scholar working on Infectious Diseases, Molecular Medicine and Epidemiology, having authored 98 papers that have together received 5.7k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (73 papers), Mycobacterium research and diagnosis (71 papers) and Quinazolinone synthesis and applications (13 papers). The work is most often cited by research in Infectious Diseases (3.8k citations), Molecular Medicine (575 citations) and Epidemiology (3.8k citations). Leonid Heifets has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Pamela J. Lindholm-Levy, Kevin O. Kisich, Michael D. Iseman, Svetlana Gelperina, N Mor, Michael H. Cynamon, M D Iseman, Max Salfinger, Michael Higgins and Charles L. Daley. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and American Journal of Respiratory and Critical Care Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact